Application of kidney and marrow-tonifying capsule in treatment of optic neuritis

A technology for optic neuritis and optic nerve, applied in the field of medicine, can solve the problems of patients with retained vision, long-term side effects, and prone to rebound, achieving high clinical value and economic benefits, alleviating pathological changes, and reducing the effect of infiltration.

Inactive Publication Date: 2021-08-13
BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the treatment of acute optic neuritis by Western medicine mostly adopts high-dose hormone shock therapy, and vasodilators and neurotrophic agents are administered at the same time. The long-term treatment of Western medicine has serious side effects, such as sleep disturbance, digestive tract discomfort, and elevated intraocular pressure. If the medication time is short Or reduce the dose too quickly, prone to rebound phenomenon after drug withdrawal
And, although 80% of patients with typical optic neuritis have good visual acuity, there are still a large number of patients with residual visual impairment symptoms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of kidney and marrow-tonifying capsule in treatment of optic neuritis
  • Application of kidney and marrow-tonifying capsule in treatment of optic neuritis
  • Application of kidney and marrow-tonifying capsule in treatment of optic neuritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0033] 1. Experimental method

[0034] EAE mouse animal model establishment and grouping: 120 SPF grade C57BL / 6 female mice, 6-8 weeks old, weighing 18-22g. They were randomly divided into 3 groups (n=40 in each group): normal control group, model group, and Bushen Yisui capsule group (3.02g / kg, the best dose in the previous study).

[0035] EAE model establishment: subcutaneously inject 0.2ml of MOG35-55 emulsion (MOG35-5550μg, complete Freund's adjuvant 100μl, inactivated Mycobacterium tuberculosis 2mg / ml) at 4 points on the back of the mouse. The model animals were intraperitoneally injected with 500 ng of pertussis toxin on the day of immunization and 48 hours later. The normal control group was replaced by normal saline. On the day of modeling, the normal control group and the model group were given intragastric administration of 0.2ml normal saline (equal to the volume of the drug intervention group), and the Bushen Yisui Capsules group was given Bushen Yisui Capsules ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a new medicinal application of a kidney and marrow-tonifying traditional Chinese medicine composition. The new application refers to the application of the kidney and marrow-tonifying traditional Chinese medicine composition in preparation of a drug for preventing and/or treating optic neuritis. The prevention and/or treatment of optic neuritis is embodied in at least one of the following aspects: 1) optic nerve demyelination and axonal injury are significantly relieved; 2) the activation of optic nerve microglial is obviously relieved; and 3) the activation of optic nerve astrocyte is obviously relieved. According to the invention, the kidney and marrow-tonifying traditional Chinese medicine composition is prepared from the following raw materials in parts by mass: 208 parts of unprocessed rehmannia roots, 208 parts of prepared rehmannia roots, 42 parts of wine-treated rhubarb roots and rhizomes, 208 parts of prepared fleeceflower roots, 125 parts of thunberg fritillary bulbs, 69 parts of leeches, 42 parts of scorpion, 69 parts of tall gastrodia tubers, 125 parts of weeping forsythia capsules and 208 parts of motherwort herbs. Research results show that the kidney and marrow-tonifying capsule can significantly relieve pathological changes caused by optic neuritis, make up for the deficiency of modern medicine in the treatment of optic neuritis and reduce impact use of large-dose hormones, with very high clinical value and economic benefits.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of Bushen Yisui capsule in treating optic neuritis. Background technique [0002] Optic neuritis is an inflammation of the optic nerve with a variety of etiologies. In temperate regions and in Caucasian populations, it is often associated with multiple sclerosis. The worldwide incidence of unilateral optic neuritis varies from 0.94 to 2.18 per 100,000 population per year. Studies have confirmed that the incidence rate of women is higher than that of men. And the incidence of optic neuritis in the northern hemisphere was higher in spring at high latitudes and in people of Nordic ancestry. Optic neuritis typically presents with subacute loss of monocular vision with pain on eye movement. Vision loss usually occurs within hours or days. At present, the treatment of acute optic neuritis by Western medicine mostly adopts high-dose hormone shock therapy, and vas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/8988A61K9/48A61K47/36A61P25/00A61P29/00A61P27/02A61K35/62A61K35/646
CPCA61K36/804A61K36/708A61K36/704A61K36/8966A61K35/62A61K35/646A61K36/8988A61K36/634A61K36/533A61K9/4866A61P25/00A61P29/00A61P27/02A61K2236/331A61K2236/39A61K2236/53A61K2236/51A61K2300/00
Inventor 樊永平杨涛康越之吴明慧
Owner BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products